soul trial oral semaglutide cardiovascular outcomes results 2025 nejm 📌 Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all-cause mortality vs sitagliptin, but tirzepatide offered no New data from the SOUL

10.3390/ijms18081638 116 YangT.LiangZ.WenC.JiangX.WangL

I used to be a little embarrassed to tell people, especially in my age bracket, that Im taking testosterone replacement, Gonzalez says

R.ChandnaR.AhmadP

This medication is not recommended for individuals who are pregnant, breastfeeding, or have a history of medullary thyroid carcinoma or endocrine neoplasia

However, this is related to the metabolic condition itself rather than GLP-1 therapy

A comprehensive study of their pleiotropic effects may elucidate their function in addressing the other several facets of metabolic disorder, thereby justifying their high cost by preventing numerous problems